Threats in bioterrorism. II: CDC category B and C agents.

A variety of agents have potential for use as weapons of biological terrorism. Knowledge of the likely organisms may be useful in preparations to mitigate the effects of a BT event. Recognition of the clinical presentation of these organisms could help physicians identify them quickly, allowing more appropriate management and possible prophylaxis of others who may have been exposed. Although many of these agents do not have specific treatments, it is important to recognize those that do. It is also important to know which infections require isolation because of potential for person-to-person spread. Table 3 summarizes important features of the CDC category B and C agents. The list of agents discussed in this article is by no means exhaustive. It is always possible that some "mad scientist" could modify an existing organism or engineer some new agent for use in biological terrorism. The possibilities are limited only by the ingenuity and depravity of those individuals who would take part in such an attack.

[1]  A. Osterhaus,et al.  Evaluation of two commercially available immunoassays for the detection of hantavirus antibodies in serum samples. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  A. Bauernfeind,et al.  Molecular Procedure for Rapid Detection ofBurkholderia mallei and Burkholderia pseudomallei , 1998, Journal of Clinical Microbiology.

[3]  M. Kende,et al.  Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. , 1996, Vaccine.

[4]  P. Padula,et al.  Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. , 1998, Virology.

[5]  J. Brown,et al.  Misidentification of Brucella species with use of rapid bacterial identification systems. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Chua,et al.  The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malaysia. , 2001, The Journal of infection.

[7]  D. Raoult,et al.  Treatment of Q fever , 1993, Antimicrobial Agents and Chemotherapy.

[8]  T J Cieslak,et al.  Clinical recognition and management of patients exposed to biological warfare agents. , 1997, Clinics in laboratory medicine.

[9]  T. Ksiazek,et al.  Laboratory diagnosis of Nipah and Hendra virus infections. , 2001, Microbes and infection.

[10]  D. Raoult,et al.  Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. , 1992, The American journal of medicine.

[11]  M. Maslow,et al.  Hantavirus pulmonary syndrome in the United States , 2001, Current infectious disease reports.

[12]  Scott Thaler,et al.  Clinical and neuroradiographic manifestations of eastern equine encephalitis. , 1997, The New England journal of medicine.

[13]  M. Brummer‐Korvenkontio,et al.  Complex-specific immunoglobulin M antibody patterns in humans infected with alphaviruses , 1986, Journal of clinical microbiology.

[14]  S. P. Reddy,et al.  Multistate outbreak of listeriosis--United States, 2000. , 2000, MMWR. Morbidity and mortality weekly report.

[15]  M. Meltzer,et al.  The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? , 1997, Emerging infectious diseases.

[16]  C E Haley,et al.  An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. , 1997, JAMA.

[17]  R. Tauxe,et al.  A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. , 1997, JAMA.

[18]  D. Waag,et al.  In Vitro Antibiotic Susceptibilities ofBurkholderia mallei (Causative Agent of Glanders) Determined by Broth Microdilution and E-Test , 2001, Antimicrobial Agents and Chemotherapy.

[19]  P. Small,et al.  Management of tuberculosis in the United States. , 2001, The New England journal of medicine.

[20]  J. A. Mobley.  Biological warfare in the twentieth century: lessons from the past, challenges for the future. , 1995, Military medicine.

[21]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[22]  M. McCarron,et al.  Castor bean intoxication. , 1990, Annals of emergency medicine.

[23]  T. Monath.  Yellow fever: a medically neglected disease. Report on a seminar. , 1987, Reviews of infectious diseases.

[24]  J. Duchin,et al.  Hantavirus Pulmonary Syndrome: A Clinical Description of 17 Patients with a Newly Recognized Disease , 1994 .

[25]  J. P. Davis,et al.  A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. , 1994, The New England journal of medicine.

[26]  G. Griffiths,et al.  Quantification of ricin toxin using a highly sensitive avidin/biotin enzyme-linked immunosorbent assay. , 1988, Journal - Forensic Science Society.

[27]  E. Segura,et al.  An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia. , 1997, Emerging infectious diseases.

[28]  P. Mead,et al.  Escherichia coli O157:H7 , 1998, The Lancet.

[29]  J. Bartlett,et al.  Glanders in a military research microbiologist. , 2001, New England Journal of Medicine.

[30]  J. Millar.  The chest film findings in 'Q' fever--a series of 35 cases. , 1978, Clinical radiology.

[31]  Morbidity and Mortality Weekly Reports.  Laboratory-acquired Human Glanders-Maryland, May 2000 , 2001, MMWR. Morbidity and mortality weekly report.

[32]  R. Gaynes,et al.  Biological and chemical terrorism: strategic plan for preparedness and response. , 2000 .

[33]  J. Childs,et al.  Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. , 1993, Science.

[34]  E. J. Young,et al.  An overview of human brucellosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  K. Chua,et al.  Treatment of acute Nipah encephalitis with ribavirin , 2001, Annals of neurology.